India Pesticides Limited is an agrochemical manufacturer producing technicals, formulations, and intermediates, with technicals representing about 73% of revenue historically. The company operates four facilities with a combined capacity of 28,300 tons of technicals and 10,200 tons of formulations, exporting to more than 35 countries. Its leading product, Pretilachlor, is used in paddy cultivation, and it is the major producer in India for that molecule. FY26 revenue crossed INR 1,078 crores, with an EBITDA margin of 18%, up from 15.9% the prior year. However, the first quarter of FY27 saw EBITDA margin fall to 15.4% due to lower volumes, higher employee and fuel costs, and a one-time write-off of export receivables of INR 2.5 crores. The competitive landscape includes many global players, but India Pesticides has carved out a niche in complex generic technicals, though it faces price pressure from Chinese imports on certain products.
The moat rests on several hard-to-replicate factors. Registration barriers are substantial: each technical registration in India costs INR 7-8 lakhs, and export registrations around INR 25 lakhs, with timelines of multiple years. The company has received 7-8 overseas registrations in the coming year and recently obtained EU technical equivalence approval for a fungicide, which will enable direct sales to European customers from November 2026. Backward integration into 2,6-DEA reduces reliance on imported intermediates, improving cost competitiveness. The Shalvis facility, its 100% subsidiary, is developing specialty molecules, including a first-in-India herbicide for export, which takes several years to replicate. Customer relationships with global agrochemical companies in Japan, the USA, and Australia, fostered through CDMO projects with sample approvals, add switching costs. While Chinese competitors offer lower prices, India Pesticides has successfully substituted imports in PEDA, which was previously over 90% imported, and has passed on raw material cost increases for sulphur-based products. The durability of these barriers is evidenced by the company's ability to maintain 18% EBITDA margins in FY26 despite raw material inflation.
The near-term is weak, with FY27 revenue growth guided to low single digits due to an erratic monsoon and geopolitical disruptions in exports. However, the structural inflection is underway. The PEDA/Pretilachlor capacity expansion to 8,500 tons was commissioned in March 2026 and is expected to reach full utilization in FY27, despite a seasonal shutdown from August to October. The Shalvis facility currently has two blocks operational, with a third herbicide block under commissioning and a fourth being planned; management intends to add two blocks per year for the next few years. By 18-24 months from now, which would be around mid-2028, Shalvis could have six to eight blocks operational, generating revenue that scales from INR 50-70 crores in FY27 to several hundred crores as it approaches the INR 1,000 crore target in five years. The new fungicide molecule, targeting 2,000 tons of capacity, is already in small-scale production, and the EU equivalence approval for a separate fungicide is expected to add INR 30-40 crores of incremental revenue from November 2026. The company also plans to improve working capital days by 10-12 days in FY27, and inventory days are expected to decline from ~200 to ~170 by Q3. By the end of this period, revenue could be trending toward INR 1,500 crores annually, with EBITDA margins recovering to the 18-20% range as volumes absorb fixed costs and backward integration lowers input costs.
Management has a record of delivering on its stated targets. In FY26, they guided to INR 1,000 crores revenue and delivered INR 1,078 crores, with an EBITDA margin of 18% against a guidance of 18-20%. They highlighted that 9M FY26 revenue was INR 808 crores with an EBITDA margin of 18.4%, putting them on track. However, the Aug 2026 call revised FY27 growth expectations down to low single digits, citing a weaker-than-expected Q1 and monsoon variability, a deviation from the earlier 20% growth guidance. Capital allocation remains prudent: FY27 capex is planned at INR 45 crores for India Pesticides and INR 90 crores for the subsidiary, largely funded through internal accruals, with only a small term loan of INR 27 crores at ~8% interest for the subsidiary. The company holds a cash balance of INR 59 crores as of June 2026 and remains debt-free at the parent level. Management has reaffirmed the long-term revenue target of INR 3,000 crores by March 2031, with Shalvis contributing INR 1,000 crores. They have consistently maintained that capex will be funded without equity dilution, and they have not raised their guidance in the face of headwinds, but they have also not abandoned their long-term plan.
The path to higher earnings rests on three pillars: Shalvis ramp-up, new product registrations, and margin recovery. Assuming FY27 revenue grows only 5% to ~INR 1,130 crores, a recovery to 15-20% growth in FY28 would put revenue around INR 1,300-1,400 crores. With EBITDA margins guided back to 18-20% as volumes improve and backward integration matures, EBITDA could reach INR 240-260 crores in FY28, up from an estimated INR 170-180 crores in FY27 (using the lower margin). The major falsifier is execution on Shalvis block commissioning; any slippage beyond the September-October 2026 date for the second block would delay the revenue contribution. Additionally, a below-normal monsoon, as forecast for the upcoming season, could severely impact paddy herbicide demand, as seen in Q1 FY27. The company has acknowledged that Chinese pricing pressure persists, and if raw material costs continue to rise without corresponding price pass-through, the 18%+ margin target may remain elusive. The watchdog metrics are inventory days (target ~170 by Q3) and working capital days (to improve 10-12 days in FY27). If the company can deliver on the Shalvis timeline and achieve the Q3 margin recovery, the long-term compounding path remains intact; if not, the cyclical vulnerability to monsoon and global pricing could keep the business in a low-growth, low-margin equilibrium.
companyname: India Pesticides Limited ticker: IPL sector: Agrochemicals / Pesticides India Pesticides Limited (IPL) is an R&D-driven agrochemical manufacturer that produces three categories of products: technicals (the active chemical ingredients that go into crop protection products), formulations (finished products ready for farm use), and active pharmaceutical ingredients (APIs) for pharmaceutical use. Incorporated in 1984 and headquartered in Lucknow, the company has built its business arou...
Read the full report →capex, margin expansion, new product segment
FY27 revenue guided at INR 70-80 crores from Shalvis and incremental sales from PEDA/Pretilachlor driven by full capacity utilization and new molecule ramp-up
Guidance maintainedconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for India Pesticides Limited and 4,900+ companies.
5-day free pass. No card required.